The useful question is what changes for users, developers or buyers, and whether the announcement stays industry context or becomes something people can actually use.

Boston Scientific Corporation announced a $1.5 billion investment in MiRus LLC, acquiring a 34% equity stake in the privately held company. The deal includes an exclusive option for Boston Scientific to purchase the MiRus TAVR system, contingent on achieving clinical and regulatory milestones. The agreement does not immediately impact Boston Scientific's 2026 earnings per share, as the investment is expected to be immaterial.

The investment centers on the SIEGEL Balloon Expandable TAVR system, a nickel-free valve designed to treat severe aortic stenosis. The device uses a rhenium alloy frame and porcine tissue leaflets, offering greater radial strength than cobalt or titanium. Its open-cell design prevents foreshortening, enabling precise placement through an 8 French sheath, which is 50% smaller than current alternatives.

MiRus has initiated the STAR pivotal trial to evaluate the SIEGEL valve's safety and effectiveness in up to 1,025 patients with severe symptomatic aortic stenosis. The trial includes patients at low, intermediate, or high risk for surgical complications. Earlier feasibility studies reported positive feedback on the valve's delivery method, nickel-free construction, and hemodynamic performance.

Boston Scientific may fully acquire the MiRus TAVR business by paying an additional $3 billion upon milestone completion, gaining 100% ownership. If exercised, MiRus would receive sales-based payments, and Boston Scientific would secure an option to acquire MiRus's mitral and tricuspid replacement valve assets. The SIEGEL TAVR system remains investigational and is not yet approved for commercial use.